Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
Paul Cauthen stunned the country music world in 2025 when he announced that he had been diagnosed with cancer, and just a few ...
A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...
Our deep pipeline and cash runway into 2030 enable IDEAYA to advance key combinations and to address multiple indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback